<DOC>
	<DOCNO>NCT01001832</DOCNO>
	<brief_summary>The purpose study ass efficacy , pharmacokinetics , safety , immunogenicity abatacept subcutaneous intravenous administration Japanese participant active rheumatoid arthritis inadequate response methotrexate .</brief_summary>
	<brief_title>Efficacy , Pharmacokinetics , Safety , Immunogenicity Study Abatacept Administered Subcutaneously Treat Rheumatoid Arthritis Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Meeting criterion American Rheumatism Association diagnosis rheumatoid arthritis ( RA ) American College Rheumatology functional Classes I , II , III . Inadequate response ( deem investigator ) methotrexate take least 3 month ( 12 week ) stable dose ( 6 8 mg/week ) 28 day prior randomization ( Day 1 ) . Stabilization requirement concomitant therapy : Oral corticosteroid treatment reduce equivalent ≤10 mg prednisolone daily 28 day stabilize least 25 28 day prior treatment ( Day 1 ) . No intraarticular , intravenous , intramuscular injection corticosteroid permit within 28 day prior randomization ( Day 1 . ) Washout requirement : Participants receive combination RA therapy discontinue follow therapy least 28 day prior treatment ( Day 1 ) : diseasemodifying antirheumatic drug ( DMARDs ) , gold ( auranofin aurothiomalate sodium ) , actarit , bucillamine , azathioprine , salazosulfapyridine , lobenzarit disodium , Dpenicillamine , cyclophosphamide , mycophenolate mofetil , mizoribine ; cyclosporin , tacrolimus , calcineurin inhibitor ; immunoadsorption column . Disease Activity Requirements : At randomization ( Day 1 ) , participant meet following disease activity criterion : Swollen joint count : 10 swollen joint ( 66 joint count ) ; tender joint count : 12 tender joint ( 68 joint count ) ; C reactive protein ( CRP ) : ≥0.8 mg/dL ( result screen visit ) . For participant receive methotrexate plus DMARDs ( washout combination therapy require ) : At screen visit , participant meet following disease activity criterion : Swollen joint count : 6 swollen joint ( 66 joint count ) ; tender joint count : 8 tender joint ( 68 joint count ) ; CRP : restriction CRP ( applicable ) . After washout , randomization ( Day 1 ) , participant must meet following disease activity criterion : Swollen joint count10 swollen joint ( 66 joint count ) tender joint count12 tender joint ( 68 joint count ) CRP : ≥0.8 mg/dL ( result screen visit ) . For whose screening period longer 4 week , CRP test need perform Day −28 Day −3 ( prior treatment Day 1 ) verify eligibility . Key Current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease . Concomitant medical condition , opinion investigator , might place participant unacceptable risk participation study . Female participant undergone breast cancer screen suspicious malignancy , possibility malignancy could reasonably exclude follow additional clinical , laboratory , diagnostic evaluation . History cancer within last 5 year ( nonmelanoma skin cell cancer cure local resection ) Existing nonmelanoma skin cell cancer remove prior first administration . Participants carcinoma situ , treat definitive surgical intervention prior study entry allow participate . Clinically significant drug alcohol abuse Any serious acute bacterial infection ( pneumonia pyelonephritis unless treat completely resolve antibiotic ) Serious , chronic , recurrent bacterial infection ( recurrent pneumonia , chronic bronchiectasis ) Those risk tuberculosis ( TB ) . Specifically , current clinical , radiographic , laboratory evidence suggestive active TB ; history active TB within last 3 year , even treat ; history active TB 3 year ago unless documentation prior antiTB treatment appropriate type duration ; latent TB successfully treat . Participants positive result TB screen test indicative latent TB eligible study unless active TB infection rule treatment latent TB isoniazid initiate least 4 week prior administration study drug participant negative finding TB chest Xray film enrollment . Herpes zoster resolve less 2 month prior enrollment Current evidence ( assessed investigator ) suggestive active latent bacterial viral infection , include human immunodeficiency virus infection . Physical examination laboratory test finding : Hepatitis B surface antigenpositive status ; hepatitis C antibodypositive status . Any following laboratory value : Hemoglobin concentration : &lt; .5 g/dL ; white blood cell count : &lt; 3,000/μL ( 3*10^9/L ) ; platelet count : &lt; 100,000/mm^3 ( 100*10^9/L ) ; serum creatinine : &gt; 2 time upper limit normal ( ULN ) ; serum alanine aminotransferase : &gt; 2 ULN ; serum aspartate aminotransferase : &gt; 2 ULN . Prohibited treatment and/or therapy : Prior exposure abatacept ( CTLA4Ig ) ; prior RA treatment biologics , antitumor necrosis factor therapy ; prior exposure investigational biologic currently approve Japan ; exposure study medication previous study within 4 week 5 halflives , whichever longer ; receipt live vaccine within 3 month administration study medication schedule receive live vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>